Hsueh Chung-Tzu, Selim Julie H, Tsai James Y, Hsueh Chung-Tsen
Chung-Tzu Hsueh, Department of Dentistry, Cathay General Hospital, Taipei 10630, Taiwan.
World J Gastroenterol. 2016 Aug 21;22(31):7080-90. doi: 10.3748/wjg.v22.i31.7080.
Liposome, albumin and polymer polyethylene glycol are nanovector formulations successfully developed for anti-cancer drug delivery. There are significant differences in pharmacokinetics, efficacy and toxicity between pre- and post-nanovector modification. The alteration in clinical pharmacology is instrumental for the future development of nanovector-based anticancer therapeutics. We have reviewed the results of clinical studies and translational research in nanovector-based anti-cancer therapeutics in advanced pancreatic adenocarcinoma, including nanoparticle albumin-bound paclitaxel and nanoliposomal irinotecan. Furthermore, we have appraised the ongoing studies incorporating novel agents with nanomedicines in the treatment of pancreatic adenocarcinoma.
脂质体、白蛋白和聚乙二醇聚合物是成功开发用于抗癌药物递送的纳米载体制剂。纳米载体修饰前后在药代动力学、疗效和毒性方面存在显著差异。临床药理学的改变对基于纳米载体的抗癌治疗的未来发展至关重要。我们回顾了晚期胰腺腺癌中基于纳米载体的抗癌治疗的临床研究和转化研究结果，包括纳米白蛋白结合型紫杉醇和纳米脂质体伊立替康。此外，我们评估了目前将新型药物与纳米药物联合用于治疗胰腺腺癌的研究。
